Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JOHN C MORRIS

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1407055700
CMS profile
199093
Location
CINCINNATI, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$16,237.63

14 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Merck Sharp & Dohme Corporation $16,164.63 13
Novartis Pharmaceuticals Corporation $73.00 1

Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JOHN C MORRIS

NPI 1407055700 · CMS profile ID 199093

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

CINCINNATI, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1407055700?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JOHN C MORRIS, NPI 1407055700, CMS profile ID 199093. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1407055700?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). JOHN C MORRIS, NPI 1407055700, CMS profile ID 199093. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1407055700?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
JOHN C MORRIS, NPI 1407055700, CMS profile ID 199093, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1407055700?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

14 matching records · $16,237.63 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 14 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–14 of 14.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Merck Sharp & Dohme Corporation $3,500.0012/09/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695855471 CMS
Merck Sharp & Dohme Corporation $25.0012/09/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695855473 CMS
Merck Sharp & Dohme Corporation $119.2812/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695847313 CMS
Merck Sharp & Dohme Corporation $3,500.0008/28/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695739853 CMS
Merck Sharp & Dohme Corporation $150.0008/28/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695739855 CMS
Merck Sharp & Dohme Corporation $451.8408/27/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695739851 CMS
Merck Sharp & Dohme Corporation $441.8008/27/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695739857 CMS
Novartis Pharmaceuticals Corporation $73.0006/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659850423 CMS
Merck Sharp & Dohme Corporation $3,500.0005/29/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695510407 CMS
Merck Sharp & Dohme Corporation $119.9405/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695485916 CMS
Merck Sharp & Dohme Corporation $384.3005/23/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695510399 CMS
Merck Sharp & Dohme Corporation $3,500.0005/07/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695457527 CMS
Merck Sharp & Dohme Corporation $4.4505/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695447383 CMS
Merck Sharp & Dohme Corporation $468.0205/02/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695457529 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $16,237.63 14
PY2020 $47.41 3
PY2021 $15.09 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021
Generated from
OP_DTL_GNRL_PGYR2021_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2022 Principal investigator $9,079.64 11
PY2021 Principal investigator $145,254.08 61
PY2020 Principal investigator $619,634.54 405
PY2019 Recipient $2,196.32 22
PY2019 Principal investigator $597,649.00 78

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

61 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 EMD Serono, Inc. $54.90 12/31/2021 Non-covered Recipient Entity
University of Cincinnati Cancer Institute
A Phase II single-arm trial to investigate tepotinib in advanced (Stage IIIb and IV) non-small cell lung cancer with MET exon 14 (METex14) skipping alterations or MET amplification (VISION) No dispute reported 06/30/2026 842915707
Principal investigator 1 Merck Sharp & Dohme Corporation $1,434.35 12/31/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI MEDICAL CENTER
A Phase III Randomized Trial of MK-3475 Versus Standard Treatment in Subjects with recurrent or metastatic head and neck cancer No dispute reported 06/30/2026 848742803
Principal investigator 1 EMD Serono, Inc. $54.90 11/30/2021 Non-covered Recipient Entity
University of Cincinnati Cancer Institute
A Phase II single-arm trial to investigate tepotinib in advanced (Stage IIIb and IV) non-small cell lung cancer with MET exon 14 (METex14) skipping alterations or MET amplification (VISION) No dispute reported 06/30/2026 842916361
Principal investigator 1 EMD Serono, Inc. $54.90 10/29/2021 Non-covered Recipient Entity
University of Cincinnati Cancer Institute
A Phase II single-arm trial to investigate tepotinib in advanced (Stage IIIb and IV) non-small cell lung cancer with MET exon 14 (METex14) skipping alterations or MET amplification (VISION) No dispute reported 06/30/2026 842915505
Principal investigator 1 EMD Serono, Inc. $54.90 09/30/2021 Non-covered Recipient Entity
University of Cincinnati Cancer Institute
A Phase II single-arm trial to investigate tepotinib in advanced (Stage IIIb and IV) non-small cell lung cancer with MET exon 14 (METex14) skipping alterations or MET amplification (VISION) No dispute reported 06/30/2026 842905059
Principal investigator 1 EMD Serono, Inc. $632.70 09/02/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase II single-arm trial to investigate tepotinib in advanced (Stage IIIb and IV) non-small cell lung cancer with MET exon 14 (METex14) skipping alterations or MET amplification (VISION) No dispute reported 06/30/2026 842911173
Principal investigator 1 Genentech, Inc. $3,000.00 09/02/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
PH III OPEN LABEL STUDY ATEZO VS BSC FOLLOWING ADJUVANT CHEMO IN STAGE IB IIIA NSCLC No dispute reported 06/30/2026 836038043
Principal investigator 1 EMD Serono, Inc. $54.90 08/31/2021 Non-covered Recipient Entity
University of Cincinnati Cancer Institute
A Phase II single-arm trial to investigate tepotinib in advanced (Stage IIIb and IV) non-small cell lung cancer with MET exon 14 (METex14) skipping alterations or MET amplification (VISION) No dispute reported 06/30/2026 842904405
Principal investigator 1 ABBVIE INC. $4,025.00 08/19/2021 Non-covered Recipient Entity
UC HEALTHCARE SYSTEM
A Phase 1b Study of Venetoclax in Combination with Pembrolizumab in Subjects with Previously Untreated NSCLC Whose Tumors have High PD-L1 Expression No dispute reported 06/30/2026 792472483
Principal investigator 1 Merck Sharp & Dohme Corporation $4,750.00 08/04/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI MEDICAL CENTER
A Phase III Randomized Trial of MK-3475 Versus Standard Treatment in Subjects with recurrent or metastatic head and neck cancer No dispute reported 06/30/2026 848742801
Principal investigator 1 EMD Serono, Inc. $54.90 07/30/2021 Non-covered Recipient Entity
University of Cincinnati Cancer Institute
A Phase II single-arm trial to investigate tepotinib in advanced (Stage IIIb and IV) non-small cell lung cancer with MET exon 14 (METex14) skipping alterations or MET amplification (VISION) No dispute reported 06/30/2026 842904607
Principal investigator 1 EMD Serono, Inc. $54.90 06/30/2021 Non-covered Recipient Entity
University of Cincinnati Cancer Institute
A Phase II single-arm trial to investigate tepotinib in advanced (Stage IIIb and IV) non-small cell lung cancer with MET exon 14 (METex14) skipping alterations or MET amplification (VISION) No dispute reported 06/30/2026 842932067
Principal investigator 1 EMD Serono, Inc. $531.30 06/22/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. No dispute reported 06/30/2026 842924103
Principal investigator 1 Genentech, Inc. $1,006.20 06/15/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
PH III OPEN LABEL STUDY ATEZO VS BSC FOLLOWING ADJUVANT CHEMO IN STAGE IB IIIA NSCLC No dispute reported 06/30/2026 836038037
Principal investigator 1 EMD Serono, Inc. $54.90 05/31/2021 Non-covered Recipient Entity
University of Cincinnati Cancer Institute
A Phase II single-arm trial to investigate tepotinib in advanced (Stage IIIb and IV) non-small cell lung cancer with MET exon 14 (METex14) skipping alterations or MET amplification (VISION) No dispute reported 06/30/2026 842932077
Principal investigator 1 EMD Serono, Inc. $54.90 04/30/2021 Non-covered Recipient Entity
University of Cincinnati Cancer Institute
A Phase II single-arm trial to investigate tepotinib in advanced (Stage IIIb and IV) non-small cell lung cancer with MET exon 14 (METex14) skipping alterations or MET amplification (VISION) No dispute reported 06/30/2026 842931985
Principal investigator 1 EMD Serono, Inc. $759.00 04/01/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. No dispute reported 06/30/2026 842923375
Principal investigator 1 EMD Serono, Inc. $759.00 04/01/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. No dispute reported 06/30/2026 842923457
Principal investigator 1 EMD Serono, Inc. $54.90 03/31/2021 Non-covered Recipient Entity
University of Cincinnati Cancer Institute
A Phase II single-arm trial to investigate tepotinib in advanced (Stage IIIb and IV) non-small cell lung cancer with MET exon 14 (METex14) skipping alterations or MET amplification (VISION) No dispute reported 06/30/2026 842900851
Principal investigator 1 EMD Serono, Inc. $100.00 03/18/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 842902565
Principal investigator 1 EMD Serono, Inc. $100.00 03/18/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 842902595
Principal investigator 1 EMD Serono, Inc. $100.00 03/18/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 842902681
Principal investigator 1 EMD Serono, Inc. $1,080.00 03/18/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 842902849
Principal investigator 1 EMD Serono, Inc. $100.00 03/18/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 842903547
Principal investigator 1 F. Hoffmann-La Roche AG $13,594.82 03/18/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI
1L NSCLC DX ALL COMER NON SQUAMOUS No dispute reported 06/30/2026 836037955
Principal investigator 1 EMD Serono, Inc. $628.00 03/02/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 842902523
Principal investigator 1 EMD Serono, Inc. $502.40 03/02/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 842902559
Principal investigator 1 EMD Serono, Inc. $54.90 02/26/2021 Non-covered Recipient Entity
University of Cincinnati Cancer Institute
A Phase II single-arm trial to investigate tepotinib in advanced (Stage IIIb and IV) non-small cell lung cancer with MET exon 14 (METex14) skipping alterations or MET amplification (VISION) No dispute reported 06/30/2026 842906297
Principal investigator 1 F. Hoffmann-La Roche AG $9,389.77 02/16/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI
1L NSCLC DX ALL COMER SQUAMOUS No dispute reported 06/30/2026 836037949
Principal investigator 1 EMD Serono, Inc. $600.00 02/04/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase II single-arm trial to investigate tepotinib in advanced (Stage IIIb and IV) non-small cell lung cancer with MET exon 14 (METex14) skipping alterations or MET amplification (VISION) No dispute reported 06/30/2026 842901965
Principal investigator 1 EMD Serono, Inc. $1,300.00 02/04/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase II single-arm trial to investigate tepotinib in advanced (Stage IIIb and IV) non-small cell lung cancer with MET exon 14 (METex14) skipping alterations or MET amplification (VISION) No dispute reported 06/30/2026 842903699
Principal investigator 1 EMD Serono, Inc. $650.00 02/04/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase II single-arm trial to investigate tepotinib in advanced (Stage IIIb and IV) non-small cell lung cancer with MET exon 14 (METex14) skipping alterations or MET amplification (VISION) No dispute reported 06/30/2026 842904079
Principal investigator 1 EMD Serono, Inc. $3,387.00 02/01/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Multicenter, Open-Label, Dose Escalation Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the DNA-PK Inhibitor M3814 in Combination with Avelumab with and without Palliative Radiotherapy in Participants with Selected Advanced Solid Tumors No dispute reported 06/30/2026 842902757
Principal investigator 1 EMD Serono, Inc. $2,461.00 02/01/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Multicenter, Open-Label, Dose Escalation Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the DNA-PK Inhibitor M3814 in Combination with Avelumab with and without Palliative Radiotherapy in Participants with Selected Advanced Solid Tumors No dispute reported 06/30/2026 842902787
Principal investigator 1 EMD Serono, Inc. $3,387.00 02/01/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Multicenter, Open-Label, Dose Escalation Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the DNA-PK Inhibitor M3814 in Combination with Avelumab with and without Palliative Radiotherapy in Participants with Selected Advanced Solid Tumors No dispute reported 06/30/2026 842902805
Principal investigator 1 EMD Serono, Inc. $3,387.00 02/01/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Multicenter, Open-Label, Dose Escalation Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the DNA-PK Inhibitor M3814 in Combination with Avelumab with and without Palliative Radiotherapy in Participants with Selected Advanced Solid Tumors No dispute reported 06/30/2026 842902827
Principal investigator 1 EMD Serono, Inc. $5,601.00 02/01/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Multicenter, Open-Label, Dose Escalation Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the DNA-PK Inhibitor M3814 in Combination with Avelumab with and without Palliative Radiotherapy in Participants with Selected Advanced Solid Tumors No dispute reported 06/30/2026 842902889
Principal investigator 1 EMD Serono, Inc. $3,387.00 02/01/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Multicenter, Open-Label, Dose Escalation Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the DNA-PK Inhibitor M3814 in Combination with Avelumab with and without Palliative Radiotherapy in Participants with Selected Advanced Solid Tumors No dispute reported 06/30/2026 842902913
Principal investigator 1 EMD Serono, Inc. $2,285.00 02/01/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Multicenter, Open-Label, Dose Escalation Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the DNA-PK Inhibitor M3814 in Combination with Avelumab with and without Palliative Radiotherapy in Participants with Selected Advanced Solid Tumors No dispute reported 06/30/2026 842903089
Principal investigator 1 EMD Serono, Inc. $1,612.00 02/01/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Multicenter, Open-Label, Dose Escalation Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the DNA-PK Inhibitor M3814 in Combination with Avelumab with and without Palliative Radiotherapy in Participants with Selected Advanced Solid Tumors No dispute reported 06/30/2026 842903147
Principal investigator 1 EMD Serono, Inc. $2,154.00 02/01/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Multicenter, Open-Label, Dose Escalation Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the DNA-PK Inhibitor M3814 in Combination with Avelumab with and without Palliative Radiotherapy in Participants with Selected Advanced Solid Tumors No dispute reported 06/30/2026 842903171
Principal investigator 1 EMD Serono, Inc. $5,473.00 02/01/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Multicenter, Open-Label, Dose Escalation Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the DNA-PK Inhibitor M3814 in Combination with Avelumab with and without Palliative Radiotherapy in Participants with Selected Advanced Solid Tumors No dispute reported 06/30/2026 842903257
Principal investigator 1 EMD Serono, Inc. $2,287.00 02/01/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Multicenter, Open-Label, Dose Escalation Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the DNA-PK Inhibitor M3814 in Combination with Avelumab with and without Palliative Radiotherapy in Participants with Selected Advanced Solid Tumors No dispute reported 06/30/2026 842903373
Principal investigator 1 EMD Serono, Inc. $2,222.00 02/01/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Multicenter, Open-Label, Dose Escalation Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the DNA-PK Inhibitor M3814 in Combination with Avelumab with and without Palliative Radiotherapy in Participants with Selected Advanced Solid Tumors No dispute reported 06/30/2026 842903391
Principal investigator 1 EMD Serono, Inc. $2,287.00 02/01/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Multicenter, Open-Label, Dose Escalation Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the DNA-PK Inhibitor M3814 in Combination with Avelumab with and without Palliative Radiotherapy in Participants with Selected Advanced Solid Tumors No dispute reported 06/30/2026 842903425
Principal investigator 1 EMD Serono, Inc. $1,580.00 02/01/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Multicenter, Open-Label, Dose Escalation Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the DNA-PK Inhibitor M3814 in Combination with Avelumab with and without Palliative Radiotherapy in Participants with Selected Advanced Solid Tumors No dispute reported 06/30/2026 842903553
Principal investigator 1 EMD Serono, Inc. $2,461.00 02/01/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Multicenter, Open-Label, Dose Escalation Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the DNA-PK Inhibitor M3814 in Combination with Avelumab with and without Palliative Radiotherapy in Participants with Selected Advanced Solid Tumors No dispute reported 06/30/2026 842903607
Principal investigator 1 EMD Serono, Inc. $1,337.00 02/01/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Multicenter, Open-Label, Dose Escalation Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the DNA-PK Inhibitor M3814 in Combination with Avelumab with and without Palliative Radiotherapy in Participants with Selected Advanced Solid Tumors No dispute reported 06/30/2026 842903635
Principal investigator 1 EMD Serono, Inc. $4,185.00 02/01/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Multicenter, Open-Label, Dose Escalation Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the DNA-PK Inhibitor M3814 in Combination with Avelumab with and without Palliative Radiotherapy in Participants with Selected Advanced Solid Tumors No dispute reported 06/30/2026 842903641
Principal investigator 1 EMD Serono, Inc. $4,231.00 02/01/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Multicenter, Open-Label, Dose Escalation Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the DNA-PK Inhibitor M3814 in Combination with Avelumab with and without Palliative Radiotherapy in Participants with Selected Advanced Solid Tumors No dispute reported 06/30/2026 842903647
Principal investigator 1 EMD Serono, Inc. $4,231.00 02/01/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Multicenter, Open-Label, Dose Escalation Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the DNA-PK Inhibitor M3814 in Combination with Avelumab with and without Palliative Radiotherapy in Participants with Selected Advanced Solid Tumors No dispute reported 06/30/2026 842903659
Principal investigator 1 EMD Serono, Inc. $4,185.00 02/01/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Multicenter, Open-Label, Dose Escalation Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the DNA-PK Inhibitor M3814 in Combination with Avelumab with and without Palliative Radiotherapy in Participants with Selected Advanced Solid Tumors No dispute reported 06/30/2026 842903735
Principal investigator 1 EMD Serono, Inc. $5,473.00 02/01/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Multicenter, Open-Label, Dose Escalation Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the DNA-PK Inhibitor M3814 in Combination with Avelumab with and without Palliative Radiotherapy in Participants with Selected Advanced Solid Tumors No dispute reported 06/30/2026 842903763
Principal investigator 1 EMD Serono, Inc. $5,473.00 02/01/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Multicenter, Open-Label, Dose Escalation Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the DNA-PK Inhibitor M3814 in Combination with Avelumab with and without Palliative Radiotherapy in Participants with Selected Advanced Solid Tumors No dispute reported 06/30/2026 842903887
Principal investigator 1 EMD Serono, Inc. $1,612.00 02/01/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Multicenter, Open-Label, Dose Escalation Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the DNA-PK Inhibitor M3814 in Combination with Avelumab with and without Palliative Radiotherapy in Participants with Selected Advanced Solid Tumors No dispute reported 06/30/2026 842904201
Principal investigator 1 EMD Serono, Inc. $4,185.00 02/01/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Multicenter, Open-Label, Dose Escalation Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the DNA-PK Inhibitor M3814 in Combination with Avelumab with and without Palliative Radiotherapy in Participants with Selected Advanced Solid Tumors No dispute reported 06/30/2026 842904247
Principal investigator 1 EMD Serono, Inc. $54.90 01/29/2021 Non-covered Recipient Entity
University of Cincinnati Cancer Institute
A Phase II single-arm trial to investigate tepotinib in advanced (Stage IIIb and IV) non-small cell lung cancer with MET exon 14 (METex14) skipping alterations or MET amplification (VISION) No dispute reported 06/30/2026 842900861
Principal investigator 1 EMD Serono, Inc. $562.40 01/20/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase II single-arm trial to investigate tepotinib in advanced (Stage IIIb and IV) non-small cell lung cancer with MET exon 14 (METex14) skipping alterations or MET amplification (VISION) No dispute reported 06/30/2026 842903899
Principal investigator 1 EMD Serono, Inc. $703.00 01/20/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase II single-arm trial to investigate tepotinib in advanced (Stage IIIb and IV) non-small cell lung cancer with MET exon 14 (METex14) skipping alterations or MET amplification (VISION) No dispute reported 06/30/2026 842904009
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,721.64 01/15/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI BARRETT CANCER CENTER
A PHASE III, MULTICENTER, RANDOMZIED, DOUBLE BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF CANAKINUMAB (IN COMBINATION WITH DOCETAXEL VERSUS DOCETAXEL ALONE IN PATIENTS WITH NON-SMALL CELL LUNG CANCER PREVIOUSLY TREATED WITH PD(L)-1 INHIBITORS AND PLATINUM BASED CHEMOTHERAPY No dispute reported 06/30/2026 800647417
Principal investigator 1 EMD Serono, Inc. $17,682.70 01/12/2021 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Multicenter, Open-Label, Dose Escalation Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the DNA-PK Inhibitor M3814 in Combination with Avelumab with and without Palliative Radiotherapy in Participants with Selected Advanced Solid Tumors No dispute reported 06/30/2026 842902883